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Three hundred fifty-two blood culture isolates of viridans group streptococci obtained from 43 U.S. medical
centers during 1993 and 1994 were characterized. Included were 48 isolates of ‘‘Streptococcus milleri,’’ 219 S.
mitis isolates, 29 S. salivarius isolates, and 56 S. sanguis isolates. High-level penicillin resistance (MIC, >4.0
mg/ml) was noted among 13.4% of the strains; for 42.9% of the strains, penicillin MICs were 0.25 to 2.0 mg/ml
(i.e., intermediate resistance). In general, amoxicillin was slightly more active than penicillin. The rank order
of activity for five cephalosporins versus viridans group streptococci was cefpodoxime5 ceftriaxone > cefprozil
5 cefuroxime >> cephalexin. The percentages of isolates resistant (MIC, >2 mg/ml) to these agents were 15,
17, 18, 20, and 96, respectively. The rates of resistance to erythromycin, tetracycline, and trimethoprim-
sulfamethoxazole were 12 to 38%. Resistance to either chloramphenicol or ofloxacin was uncommon (i.e.,
<1%). In general, among the four species, S. mitis was the most resistant and ‘‘S. milleri’’ was the most
susceptible.
Viridans group streptococci represent a group of Streptococ-
cus species which form part of the commensal bacterial flora of
the upper respiratory tracts of healthy humans. The principal
species or species groups comprising these streptococci are S.
mutans, S. salivarius, S. mitis, ‘‘S. milleri’’ (including S. angino-
sus, S. constellatus, and S. intermedius), and S. sanguis (13).
These organisms are associated with a relatively narrow spec-
trum of infections in humans, including subacute bacterial en-
docarditis usually arising in the face of previously compromised
valves (2, 11, 12) and generalized infection in neutropenic
patients. Endocarditis most often results from hematogenous
seeding from the oral cavity as a result of either poor dentition
or extensive dental manipulation. Similarly, the oropharyngeal
flora is typically the source of infection in neutropenic patients
(1, 4, 5, 7). These associations explain why the American Heart
Association recommends chemoprophylactic treatment with
agents active against viridans group streptococci for individuals
with valvular predisposition who undergo extensive dental ma-
nipulations (3). Similarly, empiric therapy of fever in neutro-
penic patients must take into account this organism group (8).
In the past, viridans group streptococci were nearly uni-
formly susceptible to b-lactam antimicrobial agents, aminogly-
cosides, tetracyclines, and macrolides. Several recent published
studies, however, indicate that antimicrobial resistance may be
emerging as a problem with viridans group streptococci (2, 8,
14). As in S. pneumoniae, b-lactam resistance appears to be the
result of alterations in penicillin-binding proteins (10). The
following questions arise. First, how common is antimicrobial
resistance today with this organism group? Second, if resis-
tance is common, what agents might remain of utility against
such strains, especially for chemoprophylaxis? These two ques-
tions served as the basis for the current investigation.
MATERIALS AND METHODS
A total of 352 unselected blood culture isolates of viridans group streptococci
were obtained in the clinical microbiology laboratories of 43 U.S. medical centers
(listed in the Acknowledgments) during 1993 and 1994. All isolates were char-
acterized in the authors’ laboratories following shipment of the growth on choc-
olate agar slants. The organisms were frozen at 2708C prior to characterization.
MICs were determined by the methods described by the National Committee
for Clinical Laboratory Standards (NCCLS) (9) with 13 antimicrobial agents by
a microdilution method in Mueller-Hinton broth supplemented with 3% lysed
horse blood and the following antibiotics at the indicated concentration ranges:
penicillin, 0.001 to 32 mg/ml; amoxicillin, 0.008 to 128 mg/ml; cephalexin, 0.015 to
512 mg/ml; cefprozil, 0.002 to 64 mg/ml; cefuroxime, 0.001 to 32 mg/ml; cefpo-
doxime, 0.001 to 32 mg/ml; ceftriaxone, 0.001 to 32 mg/ml; erythromycin, 0.004 to
128 mg/ml; tetracycline, 0.008 to 256 mg/ml; trimethoprim-sulfamethoxazole
(TMP-SMX; 1/19; TMP concentrations 5 0.001 to 32 mg/ml); chloramphenicol,
0.25 to 32 mg/ml; RP 59500, 0.004 to 64 mg/ml; and ofloxacin, 0.12 to 16 mg/ml.
Laboratory-grade powders obtained from their respective manufacturers were
used. Microdilution trays were incubated at 35 to 378C in ambient air for 22 to
24 h prior to determining the MICs. Daily test controls included Streptococcus
pneumoniae ATCC 49619, Haemophilus influenzae ATCC 49247, and H. influ-
enzae ATCC 49766.
Species identification was achieved by use of the API 20S Streptococcus iden-
tification system (BioMerieux Vitek, Hazelwood, Mo.) and selected conventional
biochemical tests by established criteria (13). Selected strains were examined
with nucleic acid probes for the genes of Enterococcus species and for S. pneu-
moniae (Accuprobe; GenProbe, San Diego, Calif.).
RESULTS AND DISCUSSION
Among the 352 isolates of viridans group streptococci ex-
amined in the study, 48 were identified as ‘‘S. milleri’’ group,
219 were identified as S. mitis, 29 were identified as S. saliva-
rius, and 56 were identified as S. sanguis. The results of the
MIC determinations with seven b-lactam antimicrobial agents
versus these 352 organisms are depicted in Table 1. Amoxicillin
MICs were generally about one-half those of penicillin for
penicillin-susceptible and -intermediate strains. These two
agents had equivalent activities against penicillin-resistant or-
ganisms. Among the five cephalosporins tested, the rank order
of activity was ceftriaxone 5 cefpodoxime . cefuroxime 5
cefprozil .. cephalexin. The results of MIC determinations
with six non-b-lactam agents against the same organisms are
given in Table 2. Broad ranges of MICs were obtained with
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erythromycin, tetracycline, and TMP-SMX, a narrower range
was obtained with pristinamycin, and very tight ranges were
obtained with chloramphenicol and ofloxacin. A summary of
the in vitro activities of the 13 antimicrobial agents examined
in the study versus four species of viridans group streptococci
is presented in Table 3. In general, isolates of ‘‘S. milleri’’ were
most susceptible; S. mitis isolates were most resistant.
The results of the present study reveal high rates of b-lactam
resistance among current blood culture isolates of viridans
group streptococci. By using penicillin MIC breakpoints re-
cently established by the NCCLS for specific application to
viridans group streptococci (9a), fewer than one-half of the
isolates would have been judged to be susceptible to penicillin.
Among 198 resistant isolates (i.e., 56% of the total), roughly
three of four (i.e., 43% of the total) were of intermediate
resistance (i.e., penicillin MICs, 0.1 to 2.0 mg/ml), with the
remaining isolates (i.e., 13% of the total) exhibiting high-level
penicillin resistance (i.e., MICs, $4.0 mg/ml). On the basis of a
resistance breakpoint of$2 mg/ml (i.e., the NCCLS amoxicillin
resistance breakpoint for S. pneumoniae), 15% of all isolates
were found to be resistant to amoxicillin. The rates of resis-
tance to cefprozil, cefuroxime, cefpodoxime, and ceftriaxone
obtained by using a common breakpoint of $2 mg/ml were
roughly equivalent (i.e., 15 to 20%). Comparisons of the MICs
for individual isolates, however, demonstrated the superior
activities of cefpodoxime and ceftriaxone. Cephalexin had lim-
ited activity versus viridans group streptococci.
Among the non-b-lactam agents examined in the study,
ofloxacin and chloramphenicol were found to have conspicu-
ously lower rates of resistance than erythromycin, tetracycline,
and TMP-SMX. With the last three agents, rates of resistance
varied between 12 and 38%. Strain-by-strain comparisons re-
vealed near linear relationships between the MICs of these
three antimicrobial agents for viridans group streptococci
(data not shown). RP 59500, a new streptogramin antimicro-
bial agent, had activity roughly comparable to that of chloram-
phenicol on a weight basis. The rates of resistance to this agent
cannot be calculated in view of the lack of defined MIC inter-
pretive criteria.
In 1979, Bourgault and colleagues (2) described the low
MICs of 12 antimicrobial agents for 63 isolates of viridans
groups streptococci from patients with endocarditis at the
Mayo Clinic. They observed only two penicillin-resistant
strains (i.e., MIC, 4.0 mg/ml), one S. mitis strain and one ‘‘S.
milleri’’ strain. Ten years later, 12 of 63 blood culture isolates
(19%) of viridans group streptococci recovered in Italy from
febrile neutropenic patients were noted to be of either inter-
mediate or high-level penicillin resistance (14). More recently,
in 1993, among 47 blood culture isolates of viridans group
streptococci recovered from febrile neutropenic patients in the
United Kingdom, 21% revealed intermediate penicillin resis-
tance and 17% had high-level resistance (8).
The results of the current investigation suggest that the rates
of antimicrobial resistance of viridans group streptococci ver-
sus penicillin and other b-lactam antimicrobial agents continue
to increase. In addition, high rates of erythromycin, TMP-
SMX, and tetracycline resistance (i.e., 12 to 38%) were ob-
served. As has been shown previously (2, 14), we also noted
higher rates of resistance among S. mitis isolates than among
the other three species of viridans group streptococci exam-
ined. Unfortunately, we did not have available for analysis
patient information pertaining to individual blood culture iso-
lates such as specific disease associations or patient antibiotic
histories. As a result, we are unable to discuss our findings in
the context of either of these two issues. Also, the number of
isolates from individual medical centers was too small to per-
mit an analysis of rates of resistance by geographic area. Rec-
ognizing that significant blood culture isolates of viridans
group streptococci are uncommon, individual institutions are
encouraged to attempt to define their own rates of resis-
tance.
The recent emergence of antimicrobial resistance compli-
TABLE 1. In vitro activities of selected b-lactam antimicrobial agents versus 352 blood culture isolates of viridans group streptococci
Antimicrobial
agent
No. (cumulative %) of isolates for which the MIC (mg/ml) is as follows: % Resistant
(breakpoint)a#0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 $64
Penicillin 8 (2) 2 (3) 20 (9) 55 (24) 69 (44) 83 (67) 23 (74) 24 (81) 21 (87) 19 (92) 22 (98) 3 (99) 2 (99) 1 (100) 13 ($4)
Amoxicillin 16 (5) 37 (15) 58 (32) 52 (46) 58 (63) 39 (74) 31 (83) 9 (85) 9 (88) 18 (93) 21 (99) 3 (99) 1 (100) 15 ($2)
Cephalexin 1 (0.3) 2 (1) 11 (4) 32 (13) 77 (35) 95 (62) 48 (76) 25 (83) 63 (100) 96 ($2)
Cefprozil 2 (0.6) 1 (1) 2 (2) 11 (5) 28 (13) 77 (34) 94 (61) 46 (74) 27 (82) 17 (87) 11 (90) 8 (92) 9 (95) 19 (100) 19 ($2)
Cefuroxime 1 (0.3) 5 (2) 11 (5) 21 (12) 48 (24) 69 (44) 64 (62) 48 (76) 21 (82) 22 (88) 15 (92) 14 (96) 7 (98) 6 (100) 20 ($2)
Cefpodoxime 7 (2) 13 (6) 34 (15) 54 (31) 83 (54) 38 (65) 49 (79) 19 (84) 10 (87) 16 (92) 17 (97) 10 (99) 1 (99) 1 (100) 15 ($2)
Ceftriaxone 2 (0.6) 3 (1) 9 (4) 34 (14) 82 (37) 65 (55) 48 (69) 47 (82) 21 (88) 23 (95) 11 (98) 6 (99) 1 (100) 17 ($2)
aMIC breakpoints for resistance are those recently defined by NCCLS for penicillin and ceftriaxone versus viridans group streptococci. For amoxicillin, the current
pneumococcal breakpoint was applied; the ceftriaxone breakpoint was used with cephalexin, cefprozil, cefuroxime, and cefpodoxime.
TABLE 2. In vitro activities of selected non-b-lactam antimicrobial agents versus 352 blood culture isolates of viridans group streptococci
Antimicrobial
agent
No. (cumulative %) of isolates for which the MIC (mg/ml) is as follows: % Resistant
(breakpoint)a#0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 $64
Erythromycin 4 (1) 31 (10) 75 (31) 90 (57) 4 (58) 4 (59) 10 (62) 30 (70) 49 (84) 22 (91) 15 (95) 2 (95) 16 (100) 38 ($1)
Tetracycline 1 (0.3) 4 (1) 3 (2) 8 (5) 96 (32) 89 (57) 14 (61) 17 (66) 13 (70) 14 (74) 14 (78) 28 (86) 39 (97) 12 (100) 12 ($8)
TMP-SMX 1 (0.3) 5 (2) 12 (5) 53 (20) 80 (43) 84 (67) 35 (77) 24 (84) 24 (90) 18 (95) 14 (99) 2 (10) 16 ($4)
Chloramphenicol 3 (1) 33 (10) 250 (81) 64 (99) 1 (99) 1 (100) 0.3 ($16)
Ofloxacin 3 (1) 50 (15) 187 (68) 103 (97) 7 (99) 2 (100) 0.6 ($8)
RP 59500 1 (0.3) 1 (0.6) 8 (3) 41 (14) 54 (30) 150 (72) 54 (88) 33 (97) 10 (100)
aMIC breakpoints for resistance are those defined by NCCLS for susceptibility tests with viridans group streptococci for all agents except TMP-SMX, for which no
breakpoints have been established. For TMP-SMX, the NCCLS resistance breakpoint for TMP-SMX versus S. pneumoniae was applied.
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cates therapy of viridans group streptococcal infections, e.g.,
endocarditis and bacteremia in the neutropenic host. However,
such infections are usually characterized by the recovery of an
isolate from representative clinical specimens. Therefore, de-
finitive therapy can be guided by in vitro susceptibility studies.
Chemoprophylaxis for dental procedures and in neutropenic
patients is more complicated. The results of the current study
suggest that oral penicillins and cephalosporins might have
limited value as prophylactic agents. The same appears to be
true of the macrolides, tetracyclines, and TMP-SMX. Ofloxa-
cin and chloramphenicol were the most consistently active
compounds in the present study. It is tempting to speculate
that ofloxacin might be useful as an agent for prophylaxis.
Unfortunately, quinolone prophylaxis in neutropenic cancer
patients has often been associated with breakthrough bactere-
mia caused by viridans group streptococci which express high-
level quinolone resistance (6, 8). Evidently, under the selective
pressure of quinolone prophylaxis, quinolone-resistant strains
arise among a previously susceptible population of viridans
group streptococci, probably in the upper respiratory tract, and
then go on to cause bacteremia. It is possible that newer quino-
lones with greater activities against gram-positive cocci might
function better as chemoprophylactic agents.
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